Enlarged admission of breast cancer patients to neoadjuvant systemic therapy (NAST) has also led to an increased usage of OSNA for assessing sentinel lymph nodes (SLN) in eligible patients undergoing surgery after completion of therapy. In consequence, significant clinical evidence could be gained demonstrating that molecular quantification of CK19 mRNA expression by OSNA performs on the same level of accuracy in detecting nodal metastases after NAST as in the conventional adjuvant setting. Accurate SLN assessment is essential as any amount of residual metastatic disease in lymph nodes constitutes an important prognostic factor.
File type:
pdf
File size:
333 KB
Release:
08-04-21
